Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network
BackgroundVEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an adult-onset autoinflammatory condition resulting in severe, often treatment-refractory inflammation. Currently, there are no established treatment guidelines for VEXAS syndrome.ObjectivesTo assess the efficacy...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2025-03-01
|
| シリーズ: | Frontiers in Pharmacology |
| 主題: | |
| オンライン・アクセス: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1539756/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
